troglitazone and Diabetes Mellitus, Gestational studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Research Excerpts

Excerpt	Relevance	Reference
" Oral glucose tolerance tests (OGTTs) and frequently sampled intravenous glucose tolerance tests (FSIGTs) were conducted on Latino women with impaired glucose tolerance and a history of gestational diabetes before and after 12 weeks of treatment with 400 mg/day troglitazone (n = 13) or placebo (n = 12)."	5.09	Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. ( Azen, SP; Berkowitz, K; Buchanan, TA; Goico, J; Kjos, SL; Marroquin, A; Ochoa, C; Peters, RK; Xiang, AH, 2000)
"We conducted a randomized placebo-controlled study to determine the effects of the thiazolidinedione compound troglitazone on whole-body insulin sensitivity (SI), pancreatic beta-cell function, and glucose tolerance in 42 Latino women with impaired glucose tolerance (IGT) and a history of gestational diabetes mellitus (GDM), characteristics that carry an 80% risk of developing NIDDM within 5 years."	5.08	Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM. ( Azen, S; Berkowitz, K; Buchanan, TA; Dunn, ME; Goico, J; Kjos, SL; Marroquin, A; Peters, R; Xiang, A, 1996)
"Treatment with troglitazone delayed or prevented the onset of type 2 diabetes in high-risk Hispanic women."	2.70	Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. ( Azen, SP; Berkowitz, K; Buchanan, TA; Goico, J; Hodis, HN; Kjos, SL; Marroquin, A; Ochoa, C; Peters, RK; Tan, S; Xiang, AH, 2002)
"Women with a history of gestational diabetes mellitus (GDM) are at increased risk of future development of type 2 diabetes."	1.39	Prediction of type 2 diabetes in women with a history of gestational diabetes using a genetic risk score. ( Cho, NH; Cho, YM; Choi, SH; Jang, HC; Jung, HS; Kim, K; Kim, SY; Kwak, SH; Lim, S; Park, KS, 2013)

Research

Studies (7)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Glucose Area Under the Curve (AUC) Breakfast

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (14.29)	18.2507
2000's	5 (71.43)	29.6817
2010's	1 (14.29)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Kwak, SH	1
Choi, SH	1
Kim, K	1
Jung, HS	1
Cho, YM	1
Lim, S	1
Cho, NH	1
Kim, SY	1
Park, KS	1
Jang, HC	1
Buchanan, TA	4
Xiang, AH	3
Peters, RK	3
Kjos, SL	4
Marroquin, A	4
Goico, J	4
Ochoa, C	3
Tan, S	1
Berkowitz, K	3
Hodis, HN	2
Azen, SP	2
Solignac, M	1
Schröder, AK	1
Tauchert, S	1
Ortmann, O	1
Diedrich, K	1
Weiss, JM	1
Kawakubo, M	1
Liu, CR	1
Liu, CH	1
Peters, R	1
Dunn, ME	1
Xiang, A	1
Azen, S	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome[NCT02789488]	Phase 4	50 participants (Actual)	Interventional	2013-09-30	Completed
Effect of Gain on Closed-Loop Insulin[NCT02065895]		8 participants (Actual)	Interventional	2013-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Glucose Area Under the Curve (AUC) Breakfast defines the total exposure to glucose during breakfast. Breakfast is typically considered the most difficult meal to control; low AUC is desirable.This outcome measure was analyzed for each of the three calibration error values (high error, no error and low error). (NCT02065895)
Timeframe: On day #1, day #2 and day #3 (each day could be 24 hours to 7 days apart from prior one, and completed within 6 week period) 8:00 AM to 2:00 PM on day following admission, with samples obtained every 10-15 minutes, for each sequence of calibration errors

Nighttime Time-in-target 5.0-8.33mmol/l (Controller Set-point Plus and Minus 15 mg/dL)

Intervention	mmol/l/min (Mean)
HIGH Error	66.8
NO Error	48.8
LOW Error	37.4

Night-time in target range 5.0-8.33, following the 3 hour controller initialization period blood glucose remained at or near target. (NCT02065895)
Timeframe: On day #1, day #2 and day #3 (each day could be 24 hours to 7 days apart from prior one, and completed within 6 week period) 12:00 AM to 6:00 AM on day following admission, with samples obtained every 10-15 minutes, for each sequence of calibration errors

Peak and Nadir Postprandial Glucose Concentration

Intervention	percentage of time in target range (Median)
HIGH Error	88
NO Errror	100
LOW Error	80

Highest and lowest glucose concentrations obtained during breakfast meal. (NCT02065895)
Timeframe: On day #1, day #2 and day #3 (each day could be 24 hours to 7 days apart from prior one, and completed within 6 week period) 8:00 AM to 12:00 PM on day following admission, with samples obtained every 10-15 minutes, for each sequence of calibration errors

Intervention	mmol/l (Mean)
	Peak glucose concentration	Nadir glucose concentration
Gain Decreased and Target Increased	11.3	6.6
Gain Increased and Target Decreased	13.3	4.5
Nadir Mean	11.8	4.8

Article	Year
Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes, 2002, Volume: 51, Issue:9 Topics: Adult; Chromans; Diabetes Mellitus, Type 2; Diabetes, Gestational; Double-Blind Method; Female; Gluc	2002
Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes. Atherosclerosis, 2008, Volume: 199, Issue:1 Topics: Adult; Carotid Artery Diseases; Chromans; Diabetes Mellitus, Type 2; Diabetes, Gestational; Disease	2008
Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM. Diabetes, 1996, Volume: 45, Issue:11 Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; California; Cholesterol, HDL; Cholesterol, LD	1996
Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. Diabetes, 2000, Volume: 49, Issue:5 Topics: Adult; Chromans; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glucose; Glucose Intolera	2000

Article	Year
Prediction of type 2 diabetes in women with a history of gestational diabetes using a genetic risk score. Diabetologia, 2013, Volume: 56, Issue:12 Topics: Adult; Chromans; Diabetes Mellitus, Type 2; Diabetes, Gestational; Disease Progression; Female; Foll	2013
[News on diabetes and public health perspectives]. Presse medicale (Paris, France : 1983), 2002, Nov-23, Volume: 31, Issue:39 Pt 1 Topics: Administration, Oral; Adult; Chromans; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitu	2002

troglitazone and Diabetes Mellitus, Gestational